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doi:10.1016/j.jmii.2011.12.020The B-cell depletion agent rituximab (RTX) is used in lymphoma and rheumatoid arthritis (RA),
and there have been several case reports of an RTX-induced reactivation of hepatitis C virus in
patients with lymphoma. However, there have been no papers detailing hepatitis C virus reac-
tivation after RTX therapy in a patient with RA. Here we report a case of RTX-induced hepatitis
C virus reactivation in a patient with RA. Physicians should be aware that a close follow-up of
liver function and viral load is mandatory after RTX therapy in patients with RA and concom-
itant hepatitis C.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Rituximab (RTX), a chimeric monoclonal antibody against
CD20 on Becells, is one agent used synergistically against
lymphoma. Due to complement-associated and antibody-f Rheumatology of Internal
tal-Kaohsiung Medical Center
ung University, Kaohsiung,
t.net (T.-T. Cheng).
an Society of Microbiology. Publdependent cellular cytotoxicity related to a depletion of
B-cells, this drug has recently been used for rheumatoid
arthritis (RA).1 However, RTX is considered to be associated
with immunosuppression, reactivation of hepatitis B,2 and
increased complications of cytomegalovirus infection.3
In addition, increasing serum hepatitis C virus (HCV) RNA
levels in patients with B-cell non-Hodgkin’s lymphomas
undergoing treatment with RTX combination chemotherapy
have been reported.4,5 So far, there have been no reports
on the adverse effects of RTX therapy in RA patients with
concomitant hepatitis C. Here we describe the case of
a patient with RA who was refractory to anti-tumor necrosisished by Elsevier Taiwan LLC. All rights reserved.
66 K.-M. Lin et al.factor (TNF) therapy and experienced HCV reactivation
upon receiving RTX therapy.Case report
A 51-year-old woman presented with symmetric arthritis
affecting her hand joints and involving more than three
joint areas, with marginal erosion of the affected hand
joints, and morning stiffness since 2003. Her serum was
positive for rheumatoid factor, and the level of anticyclic
citrullinated peptide antibodies was more than 340 U/mL.
She subsequently received combination therapy comprising
several nonbiological disease-modifying antirheumatic
drugs (DMARDs), including hydroxychloroquine, metho-
trexate, azathioprine, leflunomide, sulfasalazine, and
cyclosporine, but all these therapies failed to relieve her
symptoms.
In April 2004, during the treatment with DMARDs, sero-
logical tests revealed an elevation of alanine aminotrans-
ferase (ALT) level to 80 U/L (normal < 36 IU/L). Serum was
positive for anti-HCV antibody, and negative for hepatitis B
surface antigen. Furthermore, liver sonography revealed
parenchymal liver disease. From March 2005, the patient
received etanercept 25 mg twice a week to prevent hepa-
totoxicity induced by methotrexate-based DMARDs and to
control the persistent and active polyarthritis.
Etanercept was administered for two and half years, and
a serial follow-up of ALT levels during that period revealed
intermittent elevation of liver function to about two times
the upper limit of normal. In addition, the treatment was
not effective in controlling the patient’s RA activity.
Therefore, in January 2008, the treatment was shifted from
etanercept to B-cell depletion therapy (RTX, two 1000 mg
intravenous infusions with a 2 week interval). However, no
obvious improvement was detected 3 months after begin-
ning of this RTX treatment in terms of Disease Activity Score
28 (DAS28).
A baseline survey of liver function performed in December
2007, before RTX therapy was administered, revealedFigure 1. Changes in the liver function and viral load of hepat
aminotransferase; AST Z aspartate aminotransferase.serum aspartate aminotransferase (AST) and ALT levels of
34 U/L and 41 U/L, respectively. In addition, the viral load
of genotype 1b HCV RNA was 0.015512  106 IU/ml by
BAYER quantitative analysis (BAYER System 340 bDNA
Analyzer, US). Follow-up assessment of the AST/ALT and
HCV RNA levels (5.99454 x 106 IU/mL) in April 2008 revealed
a marked elevation of all three parameters (Fig. 1).
To assess the patient’s immune status, the lymphocyte
count was measured before RTX therapy and on the 132nd
day after RTX treatment. Lymphocyte counts were 2376/mL
and 2332/mL, respectively. The medications administered
concomitantly during this period were hydroxychloroquine
400 mg/d, the non-steroidal anti-inflammatory drug cele-
coxib 200 mg once daily, and prednisolone 5 mg/d. The
drugs and their dosages were the same as those adminis-
tered before RTX treatment.
After the diagnosis of reactivation of hepatitis C in
September 2008, the patient received weekly injections of
subcutaneous peginterferon a-2a (180 mg) plus oral ribavirin
(1000 mg daily). The patient’s DAS28 score for RA markedly
decreased from 6.73 to 4.4 over a period of 2 months. At
the same time, liver function also returned to the normal
range, and HCV RNA was undetectable 2 months later.
Subsequently, the subject received a 6-month course of
antiviral therapy.Discussion
B-cell depletion therapy is considered to be safe in RA
patients with concomitant hepatitis C.6 RTX has also been
used for the treatment of HCV-associated cryoglobulinemia
and its complications,7,8 In patients with non-Hodgkin’s
lymphoma, a deterioration in liver function has been
shown to occur when RTX is used in combination with other
chemotherapeutic agents rather than when used
separately.
In the case of our RA patient, elevated HCV RNA titer,
AST and ALT levels developed after one course of RTX
therapy. It remains to be clarified whether the differenceitis C virus (HCV) following rituximab therapy. ALT Z alanine
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patients with RA and with non-Hodgkin’s lymphoma is
related to the dose of RTX administration or to the
underlying disease. B-lymphocytes are supposed to shield
against HCV9; thus, it could be speculated that the
elevated HCV viral load reflects virus spreading from RTX-
related B-cell cytotoxicity. Otherwise, B cells serve as
antigen-presenting cells to CD4+ helper T-cells which
respond against HCV. The B cell number may be reduced
and their function may be affected due to the impact of
RTX on B-cell activity.10
There are several limitations to this case report. First,
we cannot completely exclude HCV reactivation related to
the natural course of infection or to toxicity from other
drugs, although there was an improvement in liver function
and constant medication in the 3 months prior to RTX
administration. As a result of the improvement in liver
function in the patient’s history and because of the change
in HCV RNA viral load after RTX use, we are still highly
suspicious that RTX-induced HCV reactivation indeed
occurred.
The second limitation is that the patient’s HCV RNA level
did not follow-up during the anti-TNF therapy. There were
some episodes of mildly elevated liver function tests,
which returned to baseline spontaneously or when the
doses of the hepatotoxic agents were reduced. We there-
fore suggest that this indirectly reflects the relative clinical
stability of HCV infection during anti-TNF therapy.
In addition, a decreased DAS28 score was noted after
antiviral therapy. There is in fact no evidence-based
rationale to explain why disease activity was decreased,
as indexed by DAS28, after withdrawal of RTX. We
hypothesize that the active arthritis occurring before RTX
withdrawal was associated with HCV-related extrahepatic
manifestations, including arthritis. The decreased disease
activity may partially relate to the response to antiviral
therapy.
Based on our experience with this patient with RA and
hepatitis C reactivation after RTX monotherapy, we suggest
that a close follow-up of liver function, viral load, or both is
mandatory after RTX therapy in RA patients with concom-
itant hepatitis C.References
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